Literature DB >> 2343816

Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications.

C L Grines1, D C Booth, S E Nissen, J C Gurley, K A Bennett, W N O'Connor, A N DeMaria.   

Abstract

Although acute myocardial infarction (AMI) is usually due to thrombotic occlusion when involving a native coronary artery, the mechanism responsible for AMI in patients with previous coronary artery bypass grafting (CABG) is not well understood. Since knowledge of pathophysiology of AMI may alter subsequent management, angiograms obtained between 1 hour and 7 days of AMI (median 1 day) were reviewed in 50 patients greater than 1 year after CABG. The culprit vessel was identified by the presence of residual stenosis and/or thrombus in the vessel supplying the infarct zone or by reviewing previous angiograms. The infarct vessel was identified as a vein graft in 38 (76%) patients, the native vessel in 8 patients (16%) and could not be accurately determined in 4 patients (8%). Among the 38 vein grafts suspected as the infarct vessel, unequivocal angiographic evidence of residual thrombus (filling defect/persistent staining) was present in 31 (82%) and was greater than 2 cm in length in 15 patients. Successful reperfusion occurred in only 2 of 8 (25%) grafts after intravenous thrombolytic therapy. Intragraft thrombolysis with or without additional angioplasty was successful at restoring flow in 8 of 10 (80%) grafts. Data indicate that in patients who have undergone previous CABG, AMI is usually caused by thrombotic occlusion of a saphenous vein graft and that conventional intravenous thrombolytic therapy may be inadequate to restore flow. The large mass of thrombus and absent flow in the graft may require subselective drug infusion, a higher thrombolytic dose or a mechanical means of recanalization.

Entities:  

Mesh:

Year:  1990        PMID: 2343816     DOI: 10.1016/0002-9149(90)91315-w

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Primary PTCA: Possibly the Best, Often the Only Choice for Reperfusion in Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Thrombolytic Therapy for Acute Myocardial Infarction in Patients with Prior Coronary Bypass Surgery: Results from the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Combined mechanical and thrombolytic treatment for totally occluded bypass grafts.

Authors:  C Lotan; M Mosseri; Y Rozenman; Y Hasin; M S Gotsman
Journal:  Br Heart J       Date:  1995-10

4.  Clinical characteristics and outcomes of patients with acute coronary syndrome and prior coronary artery bypass grafting in a large middle eastern cohort.

Authors:  Muath Alanbaei; Alawi A Alsheikh-Ali; Tareq Aleinati; Mohammad Zubaid; Mustafa Ridha; Fahad Alenezi; Wael Al-Mahmeed; Kadhim Sulaiman; Jawad Al-Lawati; Haitham Amin; Jassim Al Suwaidi; Ahmed Al-Motarreb
Journal:  Open Cardiovasc Med J       Date:  2011-08-30

5.  Acute coronary syndrome in patients with prior coronary artery bypass surgery: observations from a 20-year registry in a middle-eastern country.

Authors:  Rafid Al-Aqeedi; Nidal Asaad; Awad Al-Qahtani; Rajvir Singh; Hajar A Al Binali; Abdul Wahid Al Mulla; Jassim Al Suwaidi
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

6.  Debate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplasty.

Authors:  Vincent S DeGeare; Cindy L Grines
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

7.  Outcomes of Primary Percutaneous Coronary Intervention for Patients with Previous Coronary Artery Bypass Grafting Presenting with STsegment Elevation Myocardial Infarction.

Authors:  Pankaj Garg; Hazlyna Kamaruddin; Javaid Iqbal; Nigel Wheeldon
Journal:  Open Cardiovasc Med J       Date:  2015-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.